skip to main content

Montelukast neuropsychiatric effects — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

ModerateRespiratory TherapeuticsMontelukast neuropsychiatric effectsGPhC CRA

A parent says their child has nightmares and mood changes after starting montelukast. They ask whether to continue until the next routine asthma review. What is the most appropriate action?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Refer promptly because neuropsychiatric adverse effects are recognised

Montelukast is associated with neuropsychiatric reactions including sleep disturbance and mood changes. Prompt clinical review is appropriate when these symptoms emerge. In this scenario, the correct option is refer promptly because neuropsychiatric adverse effects are recognised. The other options are plausible but do not address the key clinical, legal or safety issue as directly. This aligns with UK pharmacy practice guidance cited in the reference field.

Reference: BNF; MHRA Drug Safety Update